SSE PLC (LON:SSE) Neutral Rating Reconfirmed by Analysts at JP Morgan Cazenove; With GBX 1450.00 Target; aTyr Pharma, Inc. (LIFE) Had 1 Analysts Last Week

December 7, 2017 - By Peter Erickson

Among 7 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 have Buy rating, 1 Sell and 5 Hold. Therefore 14% are positive. Life Technologies Corp had 11 analyst reports since August 25, 2015 according to SRatingsIntel. Citigroup initiated the stock with “Neutral” rating in Wednesday, December 16 report. The company was downgraded on Thursday, March 31 by William Blair. The company was maintained on Thursday, August 11 by JP Morgan. As per Wednesday, November 1, the company rating was maintained by BMO Capital Markets. The rating was downgraded by JP Morgan on Wednesday, December 14 to “Neutral”. The firm has “Hold” rating given on Tuesday, August 25 by Zacks. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) has “Sell” rating given on Thursday, September 17 by Zacks. The rating was initiated by Piper Jaffray on Thursday, September 7 with “Buy”. BMO Capital Markets maintained aTyr Pharma, Inc. (NASDAQ:LIFE) rating on Monday, August 14. BMO Capital Markets has “Hold” rating and $400 target. The rating was maintained by Citigroup on Tuesday, August 16 with “Neutral”. See aTyr Pharma, Inc. (NASDAQ:LIFE) latest ratings:

14/11/2017 Broker: J.P. Morgan Rating: Hold
01/11/2017 Broker: BMO Capital Markets Rating: Hold New Target: $4.0 Maintain
07/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $7.0 Initiate
14/08/2017 Broker: BMO Capital Markets Rating: Hold New Target: $4.0000 Maintain

SSE PLC (LON:SSE) had its stock rating noted as Neutral by analysts at JP Morgan Cazenove. JP Morgan Cazenove currently has a GBX 1450.00 target price on the 13.42B GBP market cap company or 9.39% upside potential. This was disclosed in analysts report on Thursday morning.

SSE plc produces, generates, distributes, and supplies electricity and gas, as well as other energy-related services in the United Kingdom and Ireland. The company has market cap of 13.42 billion GBP. It operates through three divisions: Wholesale, Networks, and Retail. It has a 8.38 P/E ratio. The firm generates electricity from gas, oil, coal, water, and wind.

The stock increased 0.61% or GBX 8 during the last trading session, reaching GBX 1325. About 373,394 shares traded. SSE plc (LON:SSE) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 21 analysts covering SSE PLC (LON:SSE), 10 have Buy rating, 4 Sell and 7 Hold. Therefore 48% are positive. SSE PLC has GBX 1800 highest and GBX 1150 lowest target. GBX 1516.70’s average target is 14.47% above currents GBX 1325 stock price. SSE PLC had 214 analyst reports since July 24, 2015 according to SRatingsIntel. On Thursday, March 30 the stock rating was maintained by BNP Paribas with “Outperform”. The stock has “Buy” rating by HSBC on Thursday, October 5. Societe Generale maintained the shares of SSE in report on Tuesday, January 19 with “Sell” rating. As per Wednesday, October 7, the company rating was maintained by Charles Stanley. The stock of SSE plc (LON:SSE) earned “Neutral” rating by JP Morgan on Friday, July 22. On Monday, June 12 the stock rating was maintained by Barclays Capital with “Overweight”. Morgan Stanley maintained the stock with “Overweight” rating in Thursday, April 7 report. The rating was maintained by RBC Capital Markets on Wednesday, March 9 with “Underperform”. The firm has “Underweight” rating by JP Morgan given on Thursday, November 26. The firm earned “Outperform” rating on Tuesday, January 24 by Macquarie Research.

The stock decreased 1.32% or $0.05 during the last trading session, reaching $3.75. About 30,245 shares traded. aTyr Pharma, Inc. (NASDAQ:LIFE) has risen 12.96% since December 7, 2016 and is uptrending. It has underperformed by 3.74% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Erickson




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: